Literature DB >> 23827861

Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.

John E Eaton1, Jayant A Talwalkar, Konstantinos N Lazaridis, Gregory J Gores, Keith D Lindor.   

Abstract

Primary sclerosing cholangitis (PSC), first described in the mid-1850s, is a complex liver disease that is heterogeneous in its presentation. PSC is characterized by chronic cholestasis associated with chronic inflammation of the biliary epithelium, resulting in multifocal bile duct strictures that can affect the entire biliary tree. Chronic inflammation leads to fibrosis involving the hepatic parenchyma and biliary tree, which can lead to cirrhosis and malignancy. The etiology of PSC is not fully understood, which in part explains the lack of effective medical therapy for this condition. However, we have begun to better understand the molecular pathogenesis of PSC. The recognition of specific clinical subtypes and their pattern of progression could improve phenotypic and genotypic classification of the disease. We review our current understanding of this enigmatic disorder and discuss important topics for future studies.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AIH; AIP; Autoimmune Disease; CA; CCA; CFTR; CRN; Cholangiocarcinoma; Cholestatic Liver Disease; ERCP; FISH; FXR; GBN; HCC; IAC; IBD; IL; Ig; Inflammatory Bowel Disease; JAK; LGD; LPC; LT; MAdCAM-1; MDR; MR; MRCP; PSC; T-helper; TLR; TNF; Th; Toll-like receptor; UC; UDCA; VAP-1; autoimmune hepatitis; autoimmune pancreatitis; carbohydrate antigen; cholangiocarcinoma; colorectal neoplasia; cystic fibrosis transmembrane conductance regulator; endoscopic retrograde cholangiopancreatography; farnesoid X receptor; fluorescence in situ hybridization; gallbladder neoplasia; hepatocellular carcinoma; immunoglobulin; immunoglobulin G4–associated cholangitis; inflammatory bowel disease; interleukin; janus kinase; liver transplant; low-grade dysplasia; lymphoplasmacytic; magnetic resonance; magnetic resonance cholangiopancreatography; mucosal addressin cellular adhesion molecule 1; multidrug resistance protein; primary sclerosing cholangitis; tumor necrosis factor; ulcerative colitis; ursodeoxycholic acid; vascular adhesion protein 1

Mesh:

Substances:

Year:  2013        PMID: 23827861      PMCID: PMC3815445          DOI: 10.1053/j.gastro.2013.06.052

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  169 in total

Review 1.  Management of primary sclerosing cholangitis.

Authors:  Young-Mee Lee; Marshall M Kaplan
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

2.  Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC.

Authors:  Christophe Corpechot; Ahmed El Naggar; Armelle Poujol-Robert; Marianne Ziol; Dominique Wendum; Olivier Chazouillères; Victor de Lédinghen; Daniel Dhumeaux; Patrick Marcellin; Michel Beaugrand; Raoul Poupon
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

3.  Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

Authors:  K M Boberg; A Bergquist; S Mitchell; A Pares; F Rosina; U Broomé; R Chapman; O Fausa; T Egeland; G Rocca; E Schrumpf
Journal:  Scand J Gastroenterol       Date:  2002-10       Impact factor: 2.423

4.  HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis.

Authors:  W Z Mehal; Y M Lo; B P Wordsworth; J M Neuberger; S C Hubscher; K A Fleming; R W Chapman
Journal:  Gastroenterology       Date:  1994-01       Impact factor: 22.682

5.  Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis.

Authors:  Tim O Lankisch; Jochen Metzger; Ahmed A Negm; Katja Vosskuhl; Eric Schiffer; Justyna Siwy; Tobias J Weismüller; Andrea S Schneider; Kathrin Thedieck; Ralf Baumeister; Petra Zürbig; Eva M Weissinger; Michael P Manns; Harald Mischak; Jochen Wedemeyer
Journal:  Hepatology       Date:  2011-01-03       Impact factor: 17.425

6.  Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci.

Authors:  Espen Melum; Andre Franke; Christoph Schramm; Tobias J Weismüller; Daniel Nils Gotthardt; Felix A Offner; Brian D Juran; Jon K Laerdahl; Verena Labi; Einar Björnsson; Rinse K Weersma; Liesbet Henckaerts; Andreas Teufel; Christian Rust; Eva Ellinghaus; Tobias Balschun; Kirsten Muri Boberg; David Ellinghaus; Annika Bergquist; Peter Sauer; Euijung Ryu; Johannes Roksund Hov; Jochen Wedemeyer; Björn Lindkvist; Michael Wittig; Robert J Porte; Kristian Holm; Christian Gieger; H-Erich Wichmann; Pieter Stokkers; Cyriel Y Ponsioen; Heiko Runz; Adolf Stiehl; Cisca Wijmenga; Martina Sterneck; Severine Vermeire; Ulrich Beuers; Andreas Villunger; Erik Schrumpf; Konstantinos N Lazaridis; Michael P Manns; Stefan Schreiber; Tom H Karlsen
Journal:  Nat Genet       Date:  2010-12-12       Impact factor: 38.330

7.  MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease).

Authors:  A J Grant; P F Lalor; S G Hübscher; M Briskin; D H Adams
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

8.  Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.

Authors:  Adolf Stiehl; Gerda Rudolph; Petra Klöters-Plachky; Peter Sauer; Siegfried Walker
Journal:  J Hepatol       Date:  2002-02       Impact factor: 25.083

9.  Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver.

Authors:  A Escorsell; A Parés; J Rodés; J A Solís-Herruzo; M Miras; E de la Morena
Journal:  J Hepatol       Date:  1994-11       Impact factor: 25.083

10.  Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship.

Authors:  Emmanouil Sinakos; Sunil Samuel; Felicity Enders; Edward V Loftus; William J Sandborn; Keith D Lindor
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

View more
  122 in total

Review 1.  Current and Future Burden of Chronic Nonmalignant Liver Disease.

Authors:  Prowpanga Udompap; Donghee Kim; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-17       Impact factor: 11.382

2.  Performance of magnetic resonance elastography in primary sclerosing cholangitis.

Authors:  John E Eaton; Bogdan Dzyubak; Sudhakar K Venkatesh; Thomas C Smyrk; Gregory J Gores; Richard L Ehman; Nicholas F LaRusso; Andrea A Gossard; Konstantinos N Lazaridis
Journal:  J Gastroenterol Hepatol       Date:  2016-06       Impact factor: 4.029

3.  Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.

Authors:  Nan Wu; Fanyin Meng; Tianhao Zhou; Yuyan Han; Lindsey Kennedy; Julie Venter; Heather Francis; Sharon DeMorrow; Paolo Onori; Pietro Invernizzi; Francesca Bernuzzi; Romina Mancinelli; Eugenio Gaudio; Antonio Franchitto; Shannon Glaser; Gianfranco Alpini
Journal:  FASEB J       Date:  2017-06-20       Impact factor: 5.191

4.  Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.

Authors:  John E Eaton; Kevin M Nelson; Andrea A Gossard; Elizabeth J Carey; James H Tabibian; Keith D Lindor; Nicholas F LaRusso
Journal:  Scand J Gastroenterol       Date:  2019-05-26       Impact factor: 2.423

5.  Dysregulation of antioxidant responses in patients diagnosed with concomitant Primary Sclerosing Cholangitis/Inflammatory Bowel Disease.

Authors:  Colin T Shearn; David J Orlicky; Dennis R Petersen
Journal:  Exp Mol Pathol       Date:  2017-11-24       Impact factor: 3.362

6.  A combination of liver fluke infection and traditional northeastern Thai foods associated with cholangiocarcinoma development.

Authors:  Pranee Sriraj; Thidarut Boonmars; Ratchadawan Aukkanimart; Jiraporn Songsri; Panupan Sripan; Panaratana Ratanasuwan; Sirintip Boonjaraspinyo; Nadchanan Wongchalee; Porntip Laummaunwai
Journal:  Parasitol Res       Date:  2016-06-07       Impact factor: 2.289

7.  Multiorgan chronic inflammatory hepatobiliary pancreatic murine model deficient in tumor necrosis factor receptors 1 and 2.

Authors:  Helieh S Oz
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

Review 8.  Endoscopic management of benign biliary strictures.

Authors:  Tarun Rustagi; Priya A Jamidar
Journal:  Curr Gastroenterol Rep       Date:  2015-01

9.  The 2016 diagnostic criteria for primary sclerosing cholangitis.

Authors:  Takahiro Nakazawa; Kenji Notohara; Susumu Tazuma; Atsushi Tanaka; Hiroyuki Isayama; Toshio Tsuyuguchi; Toshiyuki Mori; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2016-12-05       Impact factor: 7.527

10.  Characterization of the gut microbiota in patients with primary sclerosing cholangitis compared to inflammatory bowel disease and healthy controls.

Authors:  Samaneh Ostadmohammadi; Masoumeh Azimirad; Hamidreza Houri; Kaveh Naseri; Ehsan Javanmard; Hamed Mirjalali; Abbas Yadegar; Amir Sadeghi; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Mol Biol Rep       Date:  2021-07-25       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.